Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 111 results for thyroid

  1. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. What is the clinical and cost effectiveness of percutaneous thermal ablation for benign thyroid nodules?

    for benign thyroid nodules? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...

    Research recommendation
    Published
    10 February 2020

  4. Bipolar, schizophrenia and other psychoses: target organ damage (IND86)

    This indicator covers the percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM21

    General practice indicators suitable for use outside of QOF
    Last updated
    8 August 2019

  5. Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who have had surgery and radioactive iodine (RAI), what is the optimal duration of thyroid stimulating hormone suppression?

    NG230/04 Question Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who...

    Research recommendation
    Published
    6 January 2023

  6. Active surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness of active surveillance compared with surgery?

    surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness...

    Research recommendation
    Published
    6 January 2023

  7. Deferred

    Find out what guidance is being considered for development

  8. Coeliac disease: recognition, assessment and management (NG20)

    This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

    NICE guideline
    Published
    2 September 2015
    View recommendations

    Sections for NG20

  9. External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer?

    effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    6 January 2023

  10. Duration of follow up: What is the clinical and cost effectiveness for different durations of follow up for people with differentiated thyroid cancer who have been treated?

    effectiveness for different durations of follow up for people with differentiated thyroid cancer who have been treated? Any explanatory...

    Research recommendation
    Published
    6 January 2023

  11. Molecular tests: In fine-needle aspiration cytology (FNAC) samples that are adequate but cannot differentiate between benign and malignant samples, what is the clinical and cost effectiveness of molecular testing for thyroid cancer?

    samples, what is the clinical and cost effectiveness of molecular testing for thyroid cancer? Any explanatory notes(if applicable) For a...

    Research recommendation
    Published
    6 January 2023

  12. Transoral Endoscopic Thyroid/Parathyroid Vestibular Approach

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Coeliac disease (QS134)

    This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 October 2016
    View quality statements

    Sections for QS134

  14. Imaging for further staging: For people with differentiated thyroid cancer who have initial ultrasound evidence of extensive local spread (T2N1), what is the clinical and cost effectiveness of CT, MRI or F-18 FDG PET-CT scanning, with or without ultrasound, as part of a further staging strategy?

    Question Imaging for further staging: For people with differentiated thyroid cancer who have initial ultrasound evidence of extensive...

    Research recommendation
    Published
    6 January 2023

  15. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312